Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents [PDF]
Journal of FungiVulvovaginal candidiasis (VVC) represents a widespread gynaecological challenge, affecting approximately 75% of women at some point during their reproductive years, with a significant subset progressing to recurrent forms (RVVC).
Guillermo Quindós +6 more
doaj +2 more sources
Ibrexafungerp: a novel oral triterpenoid antifungal, as an emerging therapeutic option in Vulvovaginal Candidiasis (VVC) [PDF]
Infectious Diseases and Tropical Medicine, 2022 OBJECTIVE: Vulvovaginal candidiasis (VVC) is a major concern for women of reproductive age group affecting more than 70% of total population of the mentioned population.
D. Chakraborty, S. Choudhury, S. Lahiry
doaj +2 more sources
Draft genome sequence and annotation of the enfumafungin producing fungus Hormonema carpetanum ATCC 74360 [PDF]
BMC Genomic DataObjectives Plant endophytic fungusHormonema carpetanum is the only organism known to produce enfumafungin to date. Enfumafungin is a fernane-type triterpenoid glycoside compound with broad-spectrum antifungal activity, and this leading compound has been ...
Haodong Chen +5 more
doaj +2 more sources
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp [PDF]
Drugs in R&D, 2021 On 2 June, 2021, the US Food and Drug Administration approved ibrexafungerp (formerly MK-3118 and SCY-078) for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infection. Ibrexafungerp is the first drug approved in a novel antifungal class in more than two decades, and the Food and Drug Administration's decision was based on ...
Matthew W. McCarthy
openalex +3 more sources
Advanced ScienceEnfumafungin‐type antibiotics, represented by enfumafungin and fuscoatroside, constitute a distinct class of fungi‐derived fernane‐type triterpenoids renowned for their potent antifungal activity.
Yaohui Gao +11 more
doaj +2 more sources
Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management [PDF]
PharmaceuticsCurrently, the rising prevalence of resistant Candida species, particularly Candida albicans, as well as non-albicans isolates such as Candida glabrata and Candida krusei, represent challenges in their management.
Karolina Akinosoglou +4 more
doaj +2 more sources
Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303) [PDF]
Clinical Infectious Diseases, 2021 Abstract Background Current treatment of vulvovaginal candidiasis (VVC) is largely limited to azole therapy. Ibrexafungerp is a first-in-class triterpenoid antifungal with broad-spectrum anti-Candida fungicidal activity.
Jane R. Schwebke +15 more
openalex +3 more sources
Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm [PDF]
DiagnosticsInvasive pulmonary aspergillosis (IPA), traditionally associated with severe immunosuppression and neutropenia, is increasingly reported among non-neutropenic patients.
Rocco Morena +3 more
doaj +2 more sources
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin [PDF]
Drugs, 2021 The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture. Limited antifungal therapeutic options are further challenged by drug-drug interactions, toxicity, and ...
Martin Hoenigl +11 more
openaire +4 more sources